| 2009 |
van Geel TACM, van Helden S, Geusens PP, Winkens B, Dinant G-J. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. January 2009;68(1):99-102. |
21 |
21 |
| 2020 |
Kendler DL, Marin F, Geusens P, López-Romero P, Lespessailles E, Body J-J, Minisola S. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. Bone. January 2020;130:115113. |
0 |
0 |
| 2022 |
Geusens P, Feldman R, Oates M, Thomas T, Makras P, Jakob F, Langdahl B, Wang Z, Rojeski M, Libanati C. Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis. Bone. January 2022;154:116209. |
0 |
0 |
| 2023 |
Bevers MSAM, Heyer FL, Wyers CE, van Rietbergen B, Geusens PPMM, Janzing HMJ, Lambers Heerspink O, Poeze M, van den Bergh JP. The contribution of lower-mineralized tissue to the healing of distal radius fractures assessed using HR-pQCT. Bone. October 2023;175:116859. |
0 |
0 |
| 2020 |
Geusens P, Kendler DL, Fahrleitner-Pammer A, López-Romero P, Marin F. Distribution of prevalent and incident vertebral fractures and their association with bone mineral density in postmenopausal women in the teriparatide versus risedronate vero clinical trial. Calcif Tiss Int. June 2020;106(6):646-654. |
1 |
0 |
| 2020 |
de Bruin IJA, Vranken L, Wyers CE, van der Velde RY, Trienekens TAM, Kaarsemaker S, Janzing HMJ, Wolters FL, Wouda S, Geusens PPMM, van den Bergh JPW. The prevalence of celiac disease in a fracture liaison service population. Calcif Tiss Int. October 2020;107(4):327-334. |
0 |
0 |
| 2001 |
Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E. Risk of new vertebral fracture in the year following a fracture. JAMA. January 17, 2001;285(6):320-323. |
62 |
55 |
| 2005 |
Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. December 2005;20(12):2097-2104. |
18 |
17 |
| 2010 |
Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MCH, Weinstein RS, Whyte M. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. November 2010;25(11):2267-2294. |
62 |
45 |
| 2014 |
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Howe TS, van der Meulen MCH, Weinstein RS, Whyte MP. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. January 2014;29(1):1-23. |
58 |
42 |
| 2020 |
Tran T, Bliuc D, Pham HM, van Geel T, Adachi JD, Berger C, van den Bergh J, Eisman JA, Geusens P, Goltzman D, Hanley DA, Josse RG, Kaiser SM, Kovacs CS, Langsetmo L, Prior JC, Nguyen TV, Center JR; CaMoS Research Group. A risk assessment tool for predicting fragility fractures and mortality in the elderly. J Bone Miner Res. October 2020;35(10):1923-1934. |
1 |
1 |
| 2022 |
Bliuc D, Tran T, Adachi JD, Atkins GJ, Berger C, van den Bergh J, Cappai R, Eisman JA, van Geel T, Geusens P, Goltzman D, Hanley DA, Josse R, Kaiser S, Kovacs CS, Langsetmo L, Prior JC, Nguyen TV, Solomon LB, Stapledon C, Center JR; CaMos Research Group. Reply to: the association between cognitive decline and bone loss and fracture risk is not affected by medication with anticholinergic effect. J Bone Miner Res. May 2022;37(5):1075-1076. |
0 |
0 |
| 2022 |
Geusens P, Bevers MSAM, van Rietbergen B, Messina OD, Lespessailles E, Oliveri B, Chapurlat R, Engelke K, Chines A, Huang S, Saag KG, van den Bergh JP. Effect of denosumab compared with risedronate on bone strength in patients initiating or continuing glucocorticoid treatment. J Bone Miner Res. June 2022;37(6):1136-1146. |
0 |
0 |
| 2022 |
Vranken L, de Bruin IJA, Driessen AHM, Geusens PPM, Eisman JA, Center JR, van der Velde RY, Janzing HMJ, Kaarsemaker S, van den Bergh JP, Wyers CE. Decreased mortality and subsequent fracture risk in patients with a major and hip fracture after the introduction of a fracture liaison service: a 3-year follow-up survey. J Bone Miner Res. October 2022;37(10):2025-2032. |
1 |
1 |
| 2019 |
Daniels AM, Theelen LMA, Wyers CE, Janzing HMJ, van Rietbergen B, Vranken L, van der Velde RY, Geusens PPMM, Kaarsemaker S, Poeze M, vanden Bergh JP. Bone microarchitecture and distal radius fracture pattern complexity. J Orthop Res. August 2019;37(8):1690-1697. |
1 |
1 |
| 2018 |
Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. January 20, 2018;391(10117):230-240. |
29 |
24 |
| 2001 |
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Wasnich RD, Greenwald M, Kaufman J-M, Chesnut CH, Reginster J-Y; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. NEJM. February 1, 2001;344(5):333-340. |
71 |
54 |
| 2020 |
de Bruin IJA, Wyers CE, Souverein PC, van Staa TP, Geusens PPMM, van den Bergh JPW, de Vries F, Driessen JHM. The risk of new fragility fractures in patients with chronic kidney disease and hip fracture: a population-based cohort study in the UK. Osteoporos Int. August 2020;31(8):1487-1497. |
1 |
1 |
| 2020 |
Body J-J, Marin F, Kendler DL, Zerbini CAF, López-Romero P, Möricke R, Casado E, Fahrleitner-Pammer A, Stepan JJ, Lespessailles E, Minisola S, Geusens P. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporos Int. October 2020;31(10):1935-1942. |
0 |
0 |
| 2020 |
van den Berg P, van Haard PMM, Geusens PP, van den Bergh JP, Schweitzer DH. Characterization of fracture liaison service non-responders after invitation by home visits and questionnaires. Osteoporos Int. October 2020;31(10):2007-2015. |
0 |
0 |